@shrutipatelmd.bsky.social
1/
🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou
@cancerassassin1.bsky.social, presented at #AACR24
thelancet.com/journals/lan...
#oncology #crc
Key findings from this landmark phase 1 trial 🧵:
🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou
@cancerassassin1.bsky.social, presented at #AACR24
thelancet.com/journals/lan...
#oncology #crc
Key findings from this landmark phase 1 trial 🧵:
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
These results support the safety and potential antitumour activity of inhibiting the
immune checkpoint CISH through the administration of neoantigen-reactive CISH-knockout
TILs, with implications for ...
thelancet.com
April 29, 2025 at 8:26 PM
1/
🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou
@cancerassassin1.bsky.social, presented at #AACR24
thelancet.com/journals/lan...
#oncology #crc
Key findings from this landmark phase 1 trial 🧵:
🚨 First-in-human study of CRISPR-Cas9-edited TILs targeting the intracellular checkpoint CISH in metastatic CRC, led by my friend Dr. Emil Lou
@cancerassassin1.bsky.social, presented at #AACR24
thelancet.com/journals/lan...
#oncology #crc
Key findings from this landmark phase 1 trial 🧵: